← Back to Search

Cancer Screening for Lung Cancer

N/A

Waitlist Available

Led By Christine D Berg

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether screening for various types of cancer can reduce deaths from those cancers.

Who is the study for?

This trial is for older individuals who may be at risk of lung cancer. Participants will undergo screening methods to detect any signs of cancer early on, which could lead to better treatment outcomes.

What is being tested?

The study is testing the effectiveness of a screening questionnaire and X-ray imaging in identifying lung cancer in its early stages, with the goal of reducing mortality from this disease.

What are the potential side effects?

There are generally minimal side effects associated with completing a screening questionnaire and undergoing X-ray imaging. However, there might be some discomfort or anxiety related to the procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Lung Cancer Death Rates

Lung Cancer Deaths

Secondary study objectives

Complications of Diagnostic Evaluation Following a Positive Screening Test

Death Rates From All Causes

Deaths From All Causes

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: Lung ScreeningActive Control2 Interventions

Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial.

Group II: ControlActive Control1 Intervention

Participants receive standard medical care. Participants complete a DHQ at baseline.

Do I qualify?Apply below to find out